JP2024516430A5 - - Google Patents

Info

Publication number
JP2024516430A5
JP2024516430A5 JP2023566849A JP2023566849A JP2024516430A5 JP 2024516430 A5 JP2024516430 A5 JP 2024516430A5 JP 2023566849 A JP2023566849 A JP 2023566849A JP 2023566849 A JP2023566849 A JP 2023566849A JP 2024516430 A5 JP2024516430 A5 JP 2024516430A5
Authority
JP
Japan
Prior art keywords
amino
methyl
pyrimidine
methoxy
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/090836 external-priority patent/WO2022228578A1/en
Publication of JP2024516430A publication Critical patent/JP2024516430A/ja
Publication of JP2024516430A5 publication Critical patent/JP2024516430A5/ja
Pending legal-status Critical Current

Links

JP2023566849A 2021-04-30 2022-05-02 肺がん治療のためのピリミジニルアミノベンゼン Pending JP2024516430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021091463 2021-04-30
CNPCT/CN2021/091463 2021-04-30
PCT/CN2022/090836 WO2022228578A1 (en) 2021-04-30 2022-05-02 Pyrimidinylaminobenzenes for lung cancer treatment

Publications (2)

Publication Number Publication Date
JP2024516430A JP2024516430A (ja) 2024-04-15
JP2024516430A5 true JP2024516430A5 (cg-RX-API-DMAC7.html) 2025-06-05

Family

ID=83847794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566849A Pending JP2024516430A (ja) 2021-04-30 2022-05-02 肺がん治療のためのピリミジニルアミノベンゼン

Country Status (6)

Country Link
US (1) US20240226101A1 (cg-RX-API-DMAC7.html)
EP (1) EP4330256A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516430A (cg-RX-API-DMAC7.html)
KR (1) KR20240027583A (cg-RX-API-DMAC7.html)
CN (1) CN117561254A (cg-RX-API-DMAC7.html)
WO (1) WO2022228578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024094064A1 (en) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
CN116098873A (zh) * 2023-03-08 2023-05-12 苏州浦合医药科技有限公司 一种药物制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106279160B (zh) * 2016-03-18 2017-09-26 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
CN109311858B (zh) * 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
ES2963921T3 (es) * 2017-06-13 2024-04-03 Beijing Avlstone Biotechnology Co Ltd Compuestos de aminopirimidina, su método de preparación y uso de los mismos
EP3641818A1 (en) * 2017-06-23 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for preventing or treating cancer resistance to egfr inhibition
JP2020526499A (ja) * 2017-07-05 2020-08-31 シーエス ファーマテック リミテッド Egfrチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤
CN107266437B (zh) * 2017-07-19 2019-08-30 海南越康生物医药有限公司 N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法
MA51823A (fr) * 2018-02-12 2021-05-19 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
CN111588710B (zh) * 2019-02-21 2023-06-20 浙江大学 一种针对egfr耐药突变c797s的联用药物及用途
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Similar Documents

Publication Publication Date Title
EP3515916B1 (en) Shp2 phosphatase inhibitors and methods of use thereof
JP7493586B2 (ja) Rip1阻害化合物ならびにそれを作製および使用するための方法
JP2022546520A (ja) Rip1阻害化合物ならびにそれを作製および使用するための方法
CN108366992A (zh) 蛋白水解靶向嵌合体化合物及其制备和应用方法
JP6695353B2 (ja) Fgfr4阻害剤としてのホルミル化n−複素環式誘導体
ME02340B (me) Triciklična jedinjenja
US12415808B2 (en) Pyrrolo[1,2-b]pyridazine derivatives
WO2008076415A1 (en) Methods of using mek inhibitors
JP2003500404A5 (cg-RX-API-DMAC7.html)
JP2014528464A5 (cg-RX-API-DMAC7.html)
JP2006528231A (ja) プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物
JPWO2021060453A5 (cg-RX-API-DMAC7.html)
TWI840311B (zh) Rip1k抑制劑
JP2024517765A (ja) インテグリン阻害剤の拡大投与レジメン
EP3837261A1 (en) Thiadiazole irak4 inhibitors
HRP20110332T1 (hr) TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3
JP2024526138A (ja) 新規な化合物及びその使用
JP2025516543A5 (cg-RX-API-DMAC7.html)
JP2023002695A (ja) IRAK4阻害剤としてのピロロ[1,2-b]ピリダジン誘導体
AU2019321424A1 (en) Pyrrolo(1,2-b)pyridazine derivatives as IRAK4 inhibitors
AU2024309711A1 (en) Heteroaromatic dhodh inhibitors
HK40131580A (en) Heteroaromatic dhodh inhibitors
WO2023118092A1 (en) Pyrazolo[1,5-a]pyrido[3,2-e]pyrimidines and pyrazolo[1,5-a][1,3]thiazolo[5,4-e]pyrimidines as p2x3 inhibitors for the treatment of neurogenic disorders
JP2002114786A5 (cg-RX-API-DMAC7.html)
WO2025168756A1 (en) Pyrrolopyrazine compounds and their use in therapy